Shell Asset Management Co. Lowers Holdings in Alnylam Pharmaceuticals, Inc. (ALNY)

Shell Asset Management Co. lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 40.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,916 shares of the biopharmaceutical company’s stock after selling 3,946 shares during the period. Shell Asset Management Co.’s holdings in Alnylam Pharmaceuticals were worth $518,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 5.4% during the 1st quarter. Principal Financial Group Inc. now owns 24,525 shares of the biopharmaceutical company’s stock worth $2,921,000 after purchasing an additional 1,263 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 271,295 shares of the biopharmaceutical company’s stock worth $26,720,000 after purchasing an additional 16,110 shares during the period. Wells Fargo & Company MN grew its stake in shares of Alnylam Pharmaceuticals by 66.6% during the 2nd quarter. Wells Fargo & Company MN now owns 196,803 shares of the biopharmaceutical company’s stock worth $19,383,000 after purchasing an additional 78,675 shares during the period. Frontier Capital Management Co. LLC grew its stake in shares of Alnylam Pharmaceuticals by 33.9% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 36,200 shares of the biopharmaceutical company’s stock worth $3,565,000 after purchasing an additional 9,164 shares during the period. Finally, State of Wisconsin Investment Board grew its stake in shares of Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. State of Wisconsin Investment Board now owns 79,532 shares of the biopharmaceutical company’s stock worth $7,833,000 after purchasing an additional 1,416 shares during the period. Hedge funds and other institutional investors own 88.46% of the company’s stock.

Alnylam Pharmaceuticals stock opened at $74.38 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $63.57 and a 1 year high of $153.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.05 and a quick ratio of 10.96.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($0.41). The company had revenue of $2.07 million during the quarter, compared to analyst estimates of $22.66 million. Alnylam Pharmaceuticals had a negative net margin of 754.13% and a negative return on equity of 43.07%. Alnylam Pharmaceuticals’s revenue was down 87.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.34) EPS. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -7.75 earnings per share for the current fiscal year.

ALNY has been the topic of a number of analyst reports. JMP Securities set a $198.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 28th. BMO Capital Markets dropped their price objective on shares of Alnylam Pharmaceuticals from $125.00 to $124.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 16th. BidaskClub cut shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 10th. Morgan Stanley dropped their price objective on shares of Alnylam Pharmaceuticals from $93.00 to $87.00 and set an “equal weight” rating on the stock in a research note on Friday, September 28th. Finally, Goldman Sachs Group cut shares of Alnylam Pharmaceuticals from a “conviction-buy” rating to a “buy” rating in a research note on Monday, August 13th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $138.44.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/12/08/shell-asset-management-co-lowers-holdings-in-alnylam-pharmaceuticals-inc-alny.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Recommended Story: How Investors Use a Balance Sheet

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply